WFIKKN2

WFIKKN2 is a secreted multidomain extracellular protein that functions as a potent and selective antagonist of TGF-β family members GDF8 (myostatin) and GDF11. Its follistatin domain directly binds mature GDF8 and GDF11 and blocks their interaction with the type II receptor ActRIIB, as demonstrated by crystal structure determination at 1.39 Å resolution and alanine-scanning mutagenesis identifying specific residues required for antagonism (PMID:30814254, PMID:18596030). WFIKKN2 also binds TGF-β1, BMP2, and BMP4 with micromolar affinity but does not inhibit their signalling, functioning only as a binding protein for these ligands while selectively antagonizing GDF8/GDF11 in the nanomolar range (PMID:21054789). Compared to its paralogue WFIKKN1, WFIKKN2 is less effective at inhibiting semilatent myostatin because it lacks appreciable affinity for the myostatin propeptide (PMID:23829672).

1. 2008 High

   Identification of WFIKKN2's binding partners and domain architecture established it as a high-affinity antagonist of GDF8/GDF11, with the follistatin domain mediating growth factor binding and the NTR domain contributing to propeptide interactions.

   Evidence SPR, binding assays, and domain-deletion structure-function analysis of WFIKKN1/WFIKKN2 paralogues

   PMID:18596030

   Open questions at the time

   • No structural data for the follistatin domain or its binding interface with GDF8/GDF11
   • Mechanism of selectivity over other TGF-β family members not yet addressed
   • In vivo relevance of WFIKKN2 antagonism not demonstrated
2. 2010 High

   Demonstration that WFIKKN2 binds TGF-β1, BMP2, and BMP4 but fails to inhibit their signalling resolved the question of ligand selectivity, establishing WFIKKN2 as a selective functional antagonist of GDF8/GDF11 rather than a broad TGF-β pathway inhibitor.

   Evidence SPR for binding affinities combined with reporter gene assays for functional inhibition

   PMID:21054789

   Open questions at the time

   • Molecular basis for why binding to TGF-β1/BMP2/BMP4 does not translate to signalling inhibition is unknown
   • Physiological role of non-inhibitory binding to BMPs not addressed
3. 2013 High

   Comparative analysis with WFIKKN1 revealed that WFIKKN2 is less potent against semilatent myostatin because it lacks significant propeptide affinity, clarifying a functional divergence between the two paralogues.

   Evidence Reporter assays, receptor-binding assays, and comparative binding analysis between WFIKKN1 and WFIKKN2

   PMID:23829672

   Open questions at the time

   • Structural basis for differential propeptide binding between WFIKKN1 and WFIKKN2 unknown
   • Relative contributions of the two paralogues in vivo not determined
4. 2019 High

   Determination of the WFIKKN2 follistatin domain crystal structure and identification of specific surface residues required for GDF8 antagonism provided the first atomic-level mechanistic model for how WFIKKN2 competes with ActRIIB for growth factor binding.

   Evidence X-ray crystallography at 1.39 Å, native gel shift, SPR, alanine-scanning mutagenesis, reporter assay

   PMID:30814254

   Open questions at the time

   • No co-crystal structure of the WFIKKN2 FSD–GDF8 complex to reveal the binding interface directly
   • Contributions of domains outside the FSD to full-length antagonism incompletely characterized at structural level
   • No structure for the NTR domain or other domains of WFIKKN2
5. 2023 Medium

   Discovery that WFIKKN2 serves as a secreted ligand for DCC-family receptors and mediates bifunctional axon guidance — repelling sensory axons via Nope and attracting motor axons independently — revealed an unexpected second biological role entirely distinct from TGF-β antagonism.

   Evidence Ligand-receptor binding identification, in vivo axon guidance assays in mouse, receptor loss-of-function (preprint)

   PMID:37398498

   Open questions at the time

   • Preprint not yet peer-reviewed; independent replication pending
   • Identity of the motor axon-attracting receptor not determined
   • Whether axon guidance and GDF8/GDF11 antagonism functions are coordinated in vivo is unknown

• Key unresolved questions include the atomic structure of the full-length WFIKKN2–GDF8 complex, the molecular basis for functional selectivity (antagonism of GDF8/GDF11 versus non-inhibitory binding of BMPs), and the physiological integration of WFIKKN2's dual roles as a TGF-β family antagonist and axon guidance cue.
• No full-length WFIKKN2–GDF8 co-crystal structure
• No in vivo genetic loss-of-function studies in mammals characterizing musculoskeletal phenotype
• Mechanism by which WFIKKN2 engages DCC-family receptors structurally undefined